CMND Share Price Performance
CA$0
0.00 (0.00%)
Sorry, there is currently no price data for this company.
CMND Community Narratives
There are no narratives available yet.
Recent CMND News & Updates
No updates
Clearmind Medicine Inc. Key Details
Last Reported Earnings
Oct 31, 2023
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -2.72
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Clearmind Medicine Inc. Competitors
About CMND
- Founded
- 2017
- Employees
- n/a
- CEO
- WebsiteView website
Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.
Canadian Market Performance
- 7 Days: 0.4%
- 3 Months: 7.1%
- 1 Year: 21.0%
- Year to Date: 9.9%
In the last week, the market has stayed flat, however the Materials sector stood out, gaining 6.6%. More promisingly, the market is up 21% over the past year. Looking forward, earnings are forecast to grow by 11% annually. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.
Continue reading